Amsterdam

• Exploiting the synergistic effect of PARP inhibition with cisplatin and hyperthermia during interval cytoreductive surgery and HIPEC in ovar … Recruiting
  2024-519170-39-00 9 2025-04-07 fallopian tube cancer
• Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell L … Recruiting
  2022-501489-24-00 5 2025-03-28 First-line treatment of adult subjects with high-risk large B-cell lym
• FARE Trial Recruiting
  2023-506594-35-00 6 2025-03-24 Rectal cancer
• Metal Panel Patch Test Recruiting
  2023-507972-35-01 5 2025-03-24 Allergic contact dermatitis
• 68-Ga-FAPI-46 positron emission tomography (PET) to better visualise pancreatic and bile duct cancer. Recruiting
  2024-516486-36-00 10 2025-03-24 cholangiocarcinoma (bile duct cancer)
• PRESERVE-003: ONC-392 (Study Drug) Versus Docetaxel (Standard of Care) in Metastatic Non-small Cell Lung Cancer That Progressed on PD-1/PD-L … Recruiting
  2023-505311-20-01 5 2025-03-21 Metastatic Non-Small Cell Lung Cancer
• Biodistribution Evaluation to Reduce Administered Radiopharmaceutical Dose on LOng Axial Field of VieW PET Scanners – BELOW trial Recruiting
  2024-512906-24-00 3 2025-03-21 Cancer
• Study to evaluate efficacy and safety of inclisiran in children aged 6 to under 12 years of age with heterozygous familial hypercholesterole … Recruiting
  2024-514594-21-00 5 2025-03-13 Heterozygous Familial Hypercholesterolemia
• MEtformin as a MEtabolic iNTervention in Oesophageal adenocarcinomas to improve response to neoadjuvant chemoradiotherapy Recruiting
  2024-511626-30-00 4 2025-03-09 Oesophageal adenocarcinoma
• CD8 PET imaging in metastatic solid tumours; A phase II, open label, multi-center study of 89Zr-DF-crefmirlimab for CD8 positron emission to … Recruiting
  2024-515885-15-00 9 2025-03-04 Patients with metastatic solid tumours, where clinical data has shown
• Whole body HER3 quantification with radiolabelled Patritumab deruxtecan (HER3-DXd) PET/CT Recruiting
  2023-508233-14-00 4 2025-03-03 EGFR mutation positive advanced stage NSCLC
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab (INCA034176) and Corticosteroids as Initial Treatment for Chroni … Recruiting
  2023-510292-65-00 5 2025-02-25 chronic graft-versus-host disease
• Laparoscopic Antibiotic Lavage to Prevent intra-abdominal Abscess formation in Complicated Appendicitis (ALPACA) Recruiting
  2024-514850-59-00 5 2025-02-24 Appendicitis
• A Phase 1b Study of JNJ-79635322 with Daratumumab With or Without Lenalidomide or JNJ-79635322 with Pomalidomide for Multiple Myeloma Recruiting
  2024-515316-44-00 3 2025-02-24 Multiple Myeloma
• Pan-tumor Study of I-DXd in Subjects with Recurrent or Metastatic Solid Tumors Recruiting
  2023-509632-26-00 9 2025-02-11 Recurrent or Metastatic Solid Tumors (endometrial cancer (EC); head an
• Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Ca … Recruiting
  2022-502352-31-00 5 2025-02-10 Colorectal Cancer (CRC)
• Vericiguat in Vasospastic Angina (ViVA) Recruiting
  2022-502998-42-00 4 2025-02-10 Unequivocal epicardial and/or microvascular vasospastic angina
• A Phase 2 Study to Evaluate DNTH103 in Adults with Multifocal Motor Neuropathy (MOMENTUM) Recruiting
  2024-513128-40-00 4 2025-02-06 Multifocal Motor Neuropathy
• C2321003: A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men with Metastatic Castration-Resistant … Recruiting
  2024-511652-40-00 5 2025-02-05 METASTATIC CASTRATION RESISTANT PROSTATE CANCER
• Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With Recurrent KRAS/NRAS and BRAF Wild-type Colorectal Cancer Recruiting
  2024-513853-66-00 5 2025-02-04 KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colo
• A first-in-human, dose escalation and dose expansion study of SAR445877 in adult participants with advanced solid tumors Recruiting
  2023-507141-28-00 7 2025-01-29 Solid tumor
• Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease ( ENHANCE-CD ) Recruiting
  2023-508234-34-00 4 2025-01-27 Crohn's disease
• A phase 3 study to evaluate petosemtamab vs. investigator's choice in previously treated metastatic / recurrent head and neck cancer. Recruiting
  2023-510322-32-00 5 2025-01-27 patients with incurable, metastatic/recurrent head and neck squamous c
• Safety and efficacy of intradermal mRNA SARS-CoV-2 vaccination in patients with Fibrodysplasia Ossificans Progressiva (IVY trial) Recruiting
  2024-518686-10-00 6 2025-01-27 Fibrodyplasia Ossificans Progressiva (FOP)

Showing 361–384 of 1,112 trials